Lates News

According to Every AI Express, Pacific Securities released a research report on September 1, giving a buy rating for Junshi Biosciences (688180.SH). The rating reasons mainly include: 1) Expanding sales revenue maintaining high growth, significant improvement in operational efficiency, with cash in hand of 3.5 billion yuan; 2) 12 indications approved domestically for expanding, subcutaneous formulation expected to submit NDA within the year, and smooth progress in international layout; 3) PD-1/VEGF initiated 8 combination drugs in phase 2 clinical trials, BTLA global small lung 3 phase clinical trials expected to be completed by 2026; 4) Core pipeline has multiple catalysts, with focus on JS207 data readout. (Daily Economic News)